Beneficial effects of Nurr1 activators in models of Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis20,39–42 suggest pharmacological Nurr1 activation as an emerging approach to new therapies in neurodegeneration, and considerable progress has been made in the discovery of Nurr1 ligands as chemical tools and leads23,39,40,43,44. The gene discussed is NR4A2; the disease is early-onset autosomal dominant Alzheimer disease.